Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
- Sponsor
- Peking University People's Hospital
- Study ID
- NCT06340204
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Ewing Sarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 8 Years - 40 Years
- Healthy Volunteers
- Not accepted
Interventions
- Irinotecan Hydrochloride Liposome Injection — DRUGIrinotecan Hydrochloride Liposome Injection is given weekly by 5 doses every 6 weeks (5/6 qw).
Study Details
The investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma.
Key Dates
- Start date
- Mar 25, 2024
- Status verified
- Apr 2024
- Primary completion
- Mar 25, 2026
- Completion
- Dec 25, 2026
Study Design
- Enrollment
- 44 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Pediatricpediatric patients
- Experimental: AdultsAdult patients
Primary Outcome Measure
maximum tolerated dose (MTD) [ Time Frame: 6 weeks ]
Related Studies
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsPHASE1 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasPHASE1 · Recruiting · Inhibrx Biosciences, Inc · Scottsdale, Arizona
- Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS MalignanciesPHASE1 · Recruiting · New York Medical College · Valhalla, New York
- B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)PHASE1 · Recruiting · St. Jude Children's Research Hospital · Memphis, Tennessee